Zurich, Switzerland - On Sept. 7th, 2022, the "Top 100 Swiss Startup Award 2022," sponsored by Venturelab, was announced. HAYA Therapeutics, invested and incubated by Viva BioInnovator, was named TOP100 Swiss Startups' 8th Best Starup, and 1st in Cardiovascular & Drug Discovery sectors. The "Top 100 Swiss Startup Award" is a benchmark for the Swiss startup ecosystem. Every year, the award ceremony will invite the CEOs of the most promising Swiss startups, Swiss and international investors, executives, etc., from different fields. So far, these award-winning startups have created 11,100 jobs and raised CHF 6.1 billion—56 exits and three IPOs topped off the achievements of these innovators.
HAYA Therapeutics is a precision medicine company developing tissue-specific and cell-specific long noncoding RNAs (lncRNAs). The award demonstrates the industry and capital market's high recognition of its strength and development potential in the field of biomedicine.
In addition, HAYA Therapeutics was recently included in the top Swiss technology start up "SoonicornClub 2022"， a list of the most promising Swiss tech startups. The listed companies are based on three categories: unicorns (valuation of over a billion dollars), Soonicorns (valuations of over a few hundred million), and Minicorns (high growth early stage ventures). HAYA Therapeutics was listed as Minicorns.
